ReWalk Robotics’ (LFWD) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of ReWalk Robotics (NASDAQ:LFWD) in a research report report published on Monday morning, Benzinga reports. HC Wainwright currently has a $9.00 target price on the stock. HC Wainwright also issued estimates for ReWalk Robotics’ Q4 2024 earnings at ($0.14) EPS, FY2024 earnings at ($1.75) EPS, Q1 2025 earnings at ($0.14) EPS, Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.70) EPS, FY2026 earnings at $0.35 EPS, FY2027 earnings at $1.54 EPS and FY2028 earnings at $3.15 EPS.

ReWalk Robotics Price Performance

ReWalk Robotics stock opened at $4.98 on Monday. ReWalk Robotics has a 52 week low of $3.90 and a 52 week high of $9.10. The firm has a market cap of $42.33 million, a PE ratio of -1.74 and a beta of 1.99. The stock’s fifty day simple moving average is $5.54.

ReWalk Robotics (NASDAQ:LFWD) last released its earnings results on Tuesday, February 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.56. The firm had revenue of $6.88 million for the quarter, compared to analysts’ expectations of $7.20 million. ReWalk Robotics had a negative return on equity of 28.19% and a negative net margin of 159.76%. As a group, research analysts anticipate that ReWalk Robotics will post -1.82 earnings per share for the current year.

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic.